Oncology

News

Ipsen licenses Simcere ADC in $1bn-plus deal

Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.

News

AZ's ATR inhibitor ceralasertib flunks lung cancer test

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

R&D

Q4 Clinical trials round-up: October to December 2025

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

News

Two boxes and bottles of Rybrevant Faspro

J&J's subcutaneous Rybrevant cleared by FDA

J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.

News

AstraZeneca and Daiichi Sankyo logos next to Datroway box

Datroway filed for TNBC in EU after data delay

Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

Ipsen licenses Simcere ADC in $1bn-plus deal

AZ's ATR inhibitor ceralasertib flunks lung cancer test

Q4 Clinical trials round-up: October to December 2025

J&J's subcutaneous Rybrevant cleared by FDA

Datroway filed for TNBC in EU after data delay

Padcev/Keytruda scores again in early bladder cancer

Andexxa reaches the end of the line in the US

How to meet your physicians where they are online

Oncology

Editor's Picks